Impact Capital Partners LLC Has $298,000 Stock Holdings in Pfizer Inc. $PFE

Impact Capital Partners LLC lessened its holdings in Pfizer Inc. (NYSE:PFE) by 10.1% during the second quarter, HoldingsChannel reports. The firm owned 12,304 shares of the biopharmaceutical company’s stock after selling 1,382 shares during the quarter. Impact Capital Partners LLC’s holdings in Pfizer were worth $298,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of the business. GKV Capital Management Co. Inc. acquired a new stake in shares of Pfizer during the 1st quarter valued at $27,000. North Capital Inc. acquired a new position in Pfizer during the 1st quarter worth about $28,000. Bayforest Capital Ltd acquired a new position in Pfizer during the 1st quarter worth about $28,000. Horizon Financial Services LLC bought a new position in shares of Pfizer in the 1st quarter worth about $35,000. Finally, WPG Advisers LLC bought a new position in shares of Pfizer in the 1st quarter worth about $35,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the company. Citigroup lifted their price objective on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. UBS Group reaffirmed a “neutral” rating and issued a $28.00 target price on shares of Pfizer in a research report on Wednesday. Bank of America boosted their target price on Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday. Finally, Morgan Stanley boosted their target price on Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $28.29.

Pfizer Stock Performance

PFE stock opened at $27.21 on Thursday. The firm has a market cap of $154.68 billion, a PE ratio of 14.47, a P/E/G ratio of 0.82 and a beta of 0.55. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The business has a 50 day moving average of $24.59 and a 200-day moving average of $24.14. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $30.43.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.20. The company had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.Pfizer’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the company posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.